Combination immunotherapy shows long-term survival benefits for patients with advanced melanoma
In short: A long-term study of patients with advanced melanoma found that a combination of two immunotherapy drugs, nivolumab and ipilimumab, significantly extended survival compared to using ipilimumab alone. After a 10-year follow-up, patients receiving the combination therapy showed a median overall survival of 71.9 months, nearly double that of those receiving nivolumab alone.
Researchers conducted a randomized trial to compare three different treatment regimens for previously untreated advanced melanoma. While the study demonstrated a continued survival benefit for the combination therapy, it is limited by the fact that it only observed outcomes in a specific patient population and does not account for all possible variables in long-term cancer progression.
Why it matters: Long-term data confirms that combining specific immunotherapies can significantly extend life for patients with advanced skin cancer.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Source: Research: Wolchok et al. (2025). Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. The New England journal of medicine. · cc by-nc-nd
To cite this card, link to https://intellectplus.co.uk/app/health-research-combination-immunotherapy-shows-long-term-survival-benefits.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health · Latest · A–Z · All topics
